FDA delays GSK trametinib NDA by 3 months
This article was originally published in Scrip
GlaxoSmithKline on 1 May disclosed that the US FDA has delayed by three months the Prescription Drug User Fee Act action date for the company's MEK inhibitor trametinib as a treatment for patients with unresectable or metastatic melanoma with BRAF V600 mutations as detected by an US-approved test.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.